Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: Analysis of graft sources and long-term outcome

Journal of Clinical Oncology

Volumn 27, Issue 22, 2009, Pages 3634-3641

  Tomblyn, Michael B ^a   Arora, Mukta ^a   Baker, K Scott ^a   Blazar, Bruce R ^a   Brunstein, Claudio G ^a   Burns, Linda J ^a   Defor, Todd E ^a   Dusenbery, Kathryn E ^a   Kaufman, Dan S ^a   Kersey, John H ^a   MacMillan, Margaret L ^a   McGlave, Philip B ^a   Miller, Jeffrey S ^a   Orchard, Paul J ^a   Slungaard, Arne ^a   Tomblyn, Marcie R ^a   Vercellotti, Gregory M ^a   Verneris, Michael R ^a   Wagner, John E ^a   Weisdorf, Daniel J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; STATISTICAL SIGNIFICANCE; UMBILICAL CORD BLOOD; ADOLESCENT; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; COMPARATIVE STUDY; DONOR; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HOSPITALIZATION; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; METHODOLOGY; MORTALITY; MULTIVARIATE ANALYSIS; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MULTIVARIATE ANALYSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68949135788     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.2960     Document Type: Article

References (30)

1. Redaelli A, Laskin BL, Stephens JM, et al: A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Eur J Cancer Care (Engl) 14:53-62, 2005
2. Wheeler K, Richards S, Bailey C, et al: Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: The MRC UKALL X experience: Medical research council working party on childhood leukaemia. Br J Haematol 101:94-103, 1998
3. Hoelzer D, Gokbuget N: Recent approaches in acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol 36:49-58, 2000
4. Attal M, Blaise D, Marit G, et al: Consolidation treatment of adult acute lymphoblastic leukemia: A prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation: BGMT group. Blood 86:1619-1628, 1995
5. Hunault M, Harousseau JL, Delain M, et al: Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: A GOELAMS trial. Blood 104:3028-3037, 2004
6. Marks DI, Perez WS, He W, et al: Unrelated donor transplants in adults with philadelphianegative acute lymphoblastic leukemia in first complete remission. Blood 112:426-434, 2008
7. Bishop MR, Logan BR, Gandham S, et al: Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: A comparative analysis by the national marrow donor program and center for international blood and marrow transplant research. Bone Marrow Transplant 41:635-642, 2008
8. Yanada M, Matsuo K, Suzuki T, et al: Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: A metaanalysis. Cancer 106:2657-2663, 2006
9. Weisdorf D, Bishop M, Dharan B, et al: Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: Comparative toxicity and outcomes. Biol Blood Marrow Transplant 8:213-220, 2002
10. Bruggemann M, Raff T, Flohr T, et al: Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107:1116-1123, 2006
11. Ringden O, Labopin M, Gluckman E, et al: Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis: Acute leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (IMUST) study. Bone Marrow Transplant 19:963-968, 1997
12. Weisdorf DJ, Billett AL, Hannan P, et al: Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood 90:2962-2968, 1997
13. Kersey JH, Weisdorf DJ, Nesbit ME, et al: Comparison of autologous and allogeneic bone marrow transplantation for treatment of high risk refractory acute lymphoblastic leukemia. N Engl J Med 317:461-467, 1987
14. Goldstone AH, Richards SM, Lazarus HM, et al: In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/ maintenance chemotherapy in all patients: Final results of the international ALL trial (MRC UKALL XII/ECOG E2993). Blood 111:1827-1833, 2008
15. Chao NJ, Forman SJ, Schmidt GM, et al: Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. Blood 78:1923-1927, 1991
16. Oh H, Gale RP, Zhang MJ, et al: Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. Bone Marrow Transplant 22:253-257, 1998
17. Zhang MJ, Hoelzer D, Horowitz MM, et al: Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. the acute lymphoblastic leukemia working committee. Ann Intern Med 123:428-431, 1995
18. Kiehl MG, Kraut L, Schwerdtfeger R, et al: Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: No difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 22:2816-2825, 2004
19. Thomas X, Boiron JM, Huguet F, et al: Outcome of treatment in adults with acute lymphoblastic leukemia: Analysis of the LALA-94 trial. J Clin Oncol 22:4075-4086, 2004
20. Weisdorf DJ, Nesbit ME, Ramsay NKC, et al: Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: Prolonged survival associated with acute graft vs. host disease. J Clin Oncol 5:1348-1355, 1987
21. Weisdorf DJ, Woods WG, Nesbit ME, et al: Allogeneic bone marrow transplantation for acute lymphoblastic leukemia: Risk factors and clinical outcome. Br J Haematol 86:62-69, 1994
22. Cornelissen JJ, Carston M, Kollman C, et al: Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: Strong graft-versus-leukemia effect and risk factors determining outcome. Blood 97:1572-1577, 2001
23. Schiller G, Feig SA, Territo M, et al: Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors. Br J Haematol 88:72-78, 1994
24. Cornetta K, Laughlin M, Carter S, et al: Umbilical cord blood transplantation in adults: Results of the prospective cord blood transplantation (COBLT). Biol Blood Marrow Transplant 11:149-160, 2005
25. Bostrom B, Weisdorf DJ, Kim T, et al: Bone marrow transplantation for advanced acute leukemia: A pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide. Bone Marrow Transplant 5:83-89, 1990
26. Woods W, Ramsay N, Weisdorf D, et al: Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: Lack of superiority over cyclophosphamide containing conditioning regimens. Bone Marrow Transplant 6:9-16, 1990
27. Barker JN, Davies SM, DeFor T, et al: Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: Results of a matched-pair analysis. Blood 97:2957-2961, 2001
28. Wagner JE, Barker JN, DeFor TE, et al: Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: Influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100:1611-1618, 2002
29. Barker JN, Weisdorf DJ, DeFor TE, et al: Transplantation of two partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105: 1343-1347, 2005
30. Weisdorf D, Spellman S, Haagenson M, et al: Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: Revised definitions to predict survival. Biol Blood Marrow Transplant 14:748-758, 2008